Skip to content


BMC Proceedings

Open Access

Metalloproteinase inhibitors as a potential therapeutic approach in multiple myeloma: a preliminary study

  • A Sofia Pais1Email author,
  • A Cristina Gonçalves1, 2,
  • Catarina Geraldes1, 3,
  • José M Nascimento-Costa1, 2, 3 and
  • Ana B Sarmento-Ribeiro1, 2
BMC Proceedings20104(Suppl 2):P50

Published: 24 September 2010


Multiple MyelomaMyeloma CellBone Marrow Stromal CellMyeloma Cell LineMultiple Myeloma Cell

Multiple Myeloma (MM) is one of the B-cell malignancies with a poor prognosis, characterized by the clonal expansion of neoplastic plasma cells within the bone marrow, elevated serum immunoglobulin, and osteolytic bone disease. The first pathogenic step is a premalignant monoclonal gamopathy of undetermined significance (MGUS). With progression of MGUS to myeloma, complex genetic/epigenetic events occur in the neoplastic plasma cell, and in the bone marrow microenvironment. The resultant interactions of myeloma cells, bone marrow stromal cells, and microvessels contribute to persistence of the tumour and resistance to drugs. Matrix metalloproteinases (MMPs) play a critical rule in bone remodeling (osteolitic lesions) and tumor invasion, and could be a new therapeutic target in MM.

The aim of this study is to evaluate the therapeutic potential of a metalloproteinase inhibitor, batimastat (BB-94), in a multiple myeloma cell line in culture.

For this purpose a MM cell line, the NCI-H929 [H929] cells were cultured in absence and presence of different concentrations of the MMP inhibitor, BB-94, during different periods of time. Cell viability and death was determined by the alamar blue assay and by flow cytometry using the annexin V/propidium iodide incorporation.

Our preliminary results show that BB-94 has, along a broad concentration range, an antiproliferative effect in MM cells that is accompanied by a cytotoxic effect as results of increased apoptosis levels as the concerntratio increases from 1 to 5µM .

This study suggests that batimastat could be a new therapeutic approach in multiple myeloma in monotherapy.

Authors’ Affiliations

Faculty of Medicine, University of Coimbra, Coimbra, Portugal
Center of Investigation on Environment, Genetics and Oncobiology (CIMAGO), Faculty of Medicine, University of Coimbra, Coimbra, Portugal
University Hospital of Coimbra, Coimbra, Portugal


© Pais et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.